A randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohns disease: Good safety profile but lack of efficacy

Introduction: Complementary therapies are frequently used by patients with inflammatory bowel diseases. Aim: The aim of this study was to evaluate the efficacy and safety of long-term therapy with a new Boswellia serrata extract (Boswelan®, PS0201Bo) in maintaining remission in patients with Crohn's disease. Methods: In 22 German centers a double-blind, placebo-controlled, randomized, parallel study was performed. 108 outpatients with Crohn's disease in clinical remission were included. Patients were randomized to Boswelan® (3×2 capsules/day; 400mg each) or placebo for 52 weeks. The primary endpoint was the prop…